Pharmacy Practice
Affordable Medicines
Biosimilars
Compliance
Compounding
Drug Approvals
Geriatrics
Hospital/Health System
In-Pharmacy Vaccines
Law
Medication Management
News & Trends
OTC
Pharmacist Resources
Specialty Pharmacy
Technology
Disease State
Allergy
Autoimmune
Breast Cancer
Cardiovascular
Cold & Flu
COVID-19
Dermatology
Diabetes
Gastroenterology
Hematology
HIV/AIDS
Infectious Disease
Infusion
Lung Cancer
Mental Health
mRNA Technology
Neurology
Oncology
Ophthalmology
Orthopedics
Pain Management
Pediatrics
Respiratory
Schizophrenia
Urology/Nephrology
Women’s Health
Health Awareness Month
Videos
Patient Teaching Aid
Publications
Featured Issue
Featured Supplements
Conference Coverage
Continuing Education
Subscribe
COVID-19 Resources
October 2019
Digital Magazine
Archives
Subscription
Features
Assessing Cardiovascular Data for Emerging Diabetes Agents
New Drug Review 2019
Review of Selected NMEs 2019
Unlocking the Full Potential of Self-Monitoring of Blood Glucose
When Company Policy Conflicts With Pharmacy Practice Laws
Departments
Contemporary Compounding
Clotrimazole 2%, Ibuprofen 2%, Metronidazole 2%, Nifedipine 0.2%, and Dexpanthenol 3% in PracaSil-Plus
Editorial
Repairing Dysfunctional Insulin Release
Pharmacy Focus
Benefits and Risks of Facial Fillers
Senior Care
Avoiding Drug-Induced Hypoglycemia in the Older Adult
TrendWatch
Modifiable Risk Factors for Diabetes Complications
X
April 2024
In This Issue
Digital Magazine
Archives
Subscription
Continuing Education
$7.95 Per CE Exam or $69 for 12 Lessons
• April 2026
• 2.00 Credits
Managing HIV Coinfections and Complications
Pain Management
• March 2026
• 2.00 Credits
Updated Guidance for Opioid Use in Pain Management
Cardiovascular
• February 2026
• 2.00 Credits
Managing Modifiable Risk Factors in Chronic Coronary Disease
×
Full Image